DOI:
10.1055/s-00000036
Laryngo-Rhino-Otologie
LinksClose Window
References
Zhu FC, Guan XH, Li YH. et al.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older a randomised, double-blind, placebo-controlled, phase 2 trial.
The Lancet 2020;
396: 479-488
DOI: 10.1016/s0140-6736(20)31605-6.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.